<DOC>
	<DOCNO>NCT01469013</DOCNO>
	<brief_summary>This Phase 2b , outpatient , randomize , double-blinded ( single-blind extension ) , placebo-controlled , dose-ranging , parallel-group study LY3009104 Japanese participant active rheumatoid arthritis ( RA ) background methotrexate ( MTX ) therapy . LY3009104 orally administer day background methotrexate ( 6 16 mg/week ) therapy 12 week double-blind treatment period ( 1 , 2 , 4 8 mg/day , placebo ) , 52 week single-blind extension period ( 4 8 mg/day ) .</brief_summary>
	<brief_title>Oral JAK1/JAK2 Selective Inhibitor Treatment Japanese Participants With Active Rheumatoid Arthritis Background Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Ambulatory male female age 20 75 year , inclusive , time study entry Diagnosis adultonset RA ( least 6 month duration longer 15 year prior screen ) accord 2010 ACR/EULAR classification criterion RA Have active RA define least 6 swollen least 6 tender joint base 66/68 joint count Regular use MTX least 12 week , treatment stable dose 6 16 mg/week ( 2 3 time week ) least 8 week prior treatment period . The dose MTX remain stable throughout study , may adjust safety reason . For participant receive corticosteroid , must dose exceed 10 mg prednisone daily ( equivalent ) dose regimen least 6 week prior treatment period Have CReactive Protein ( CRP ) measurement &gt; 0.5 mg/dL Erythrocyte Sedimentation Rate ( ESR ) &gt; 28 mm/hr . The CRP ESR may repeat screen period discretion investigator , repeat result may accept study eligibility purpose Use nonsteroidal antiinflammatories ( NSAIDs ) less 4 week prior treatment period . If NSAIDs , must stable dose drug least 4 week prior treatment period must remain stable dose throughout study Received prior treatment oral JAK inhibitor regardless receive Have diagnosis Felty 's syndrome Evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Have hepatitis C virus ( HCV ; positive antihepatitis C antibody confirm presence HCV ) Positive hepatitis B surface antigen [ HBsAg+ ] , OR negative hepatitis B surface antigen [ HBsAg ] , positive hepatitis B core antibody ( HBcAb+ ) and/or positive hepatitis B surface antibody ( HBsAb+ ) positive Hepatitis B virus ( HBV ) DNA ( ≥2.1 Log copy/mL Polymerase Chain Reaction [ PCR ] method ) detect serum Have positive result QuantiFERON®TB Gold test purify protein derivative ( PPD ) test Have estimate Glomerular Filtration Rate ( GFR ) serum creatinine use Modification Diet Renal Disease ( MDRD ) method &lt; 50 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>